SVF-002 is under clinical development by Svenska Vaccinfabriken Produktion and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SVF-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SVF-002 overview

SVF-002 is under development for the prevention of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It acts by targeting SARS CoV-2 spike glycoprotein.

Svenska Vaccinfabriken Produktion overview

Svenska Vaccinfabriken Produktion (SVF) is a biotech-based research company. Its main business activity includes the development of vaccines and immunotherapies for life-threatening diseases. SVF’s product portfolio includes SVF- 001, Chronic HBV and HBV/HDV Therapeutic vaccine and SVF-003, a Crimean Congo Hemorrhagic Fever Prophylactic vaccine. Its other pipeline include SVF-004 and SVF 002. The company operates through its partnership with Karolinska Institutet and the OpenCorona consortium. SVF is headquartered in Stockholm, Sweden.

For a complete picture of SVF-002’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.